Global Phenylketonuria (PKU) Treatment Market - Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Jul 2019
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Phenylketonuria (PKU) Treatment Market ­By Type (Hyperphenylalaninemia, Mild PKU, Moderate or Variant and Classic PKU), Drugs Type (Kuvan, Sapropterin, Palynziq, Pagvaliase, Biopten), Therapy Type (Gene Therapy, Dietary Therapy), Route of Administration (Oral, Intravenous, Subcutaneous and Others), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026

Market Analysis: Global Phenylketonuria (PKU) Treatment Market 

Global Phenylketonuria (PKU) Treatment Market is rising at substantial CAGR in the forecast period of 2019-2026. This rise in market can be attributed to increasing incidence rate of phenylketonuria, growing research in the field of genomics and biotechnology, increasing awareness about the phenylketonuria, change in lifestyle of the people, rising per capita income in emerging markets and development in the health care industry.

Market Definition: Global Phenylketonuria (PKU) Treatment Market 

Phenylketonuria is a rare inherited genetic disorder that leads to the increase in levels of phenylalanine in blood. Phenylalanine is an amino acid which is comprised of proteins obtained from food and diet. Phenylalanine hydroxylase enzyme converts phenylalanine in to tyrosine amino acid in human body. The tyrosine is required to create neurotransmitters, such as epinephrine, norepinephrine and dopamine in human body. Phenylketonuria is caused due to a defect in the gene which helps to produce phenylalanine hydroxylase. Absence of this enzyme leads to a buildup of phenylalanine in the body and starts getting stored in the blood stream and consequently, damaging the brain. The patient of phenylketonuria can develop symptoms such as seizures, skin conditions, tremors or trembling and shaking, hyperactivity, stunted growth and more. The incidence of phenylketonuria is approximately 1 in 10,000 in European populations, although it is less common in the African-American population, with an incidence of approximately 1 in 50,000. Phenyketonuria is rare in Finland and Japan, although its incidence may vary markedly between different regions. Market Drivers

  • Increasing incidence rate of phenylketonuria is driving the market growth
  • Increasing awareness amongst the people is enhancing the market growth
  • Growing research in the field of genomics and bioinformatics is flourishing the market growth
  • Changing lifestyle is encouraging the market growth
  • Advancements in the health care industry and rising per capita income in emerging markets

Market Restraints

  • Overall high cost of treatment is hampering the market growth
  • Stringent government regulations is hindering the market growth
  • Unfavorable reimbursement is acting as a restraint for the market growth
  • Lack of awareness among the patient and physician about Phenylketonuria is a hindering factor for the market growth

Segmentation: Global Phenylketonuria (PKU) Treatment Market 

By Type

  • Hyperphenylalaninemia
  • Mild PKU
  • Moderate or Variant
  • Classic PKU

By Drug Type

  • Kuvan
  • Sapropterin
  • Palynziq
  • Pagvaliase
  • Biopten

By Therapy Type

  • Gene Therapy
  • Dietary Therapy

By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Argentina
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In May 2019, BioMarin received approval from the European Commission for Palynziq (pegvaliase injection) for the treatment of phenylketonuria (PKU) in patients. This drug is able to offer this important new therapy to the adults with PKU who are unable to control their [phenylalanine] levels with existing options
  • In May 2017, BioMarin received approval from FDA for pegvaliase-pqpz (Palynziq), a drug for the treatment of phenylketonuria (PKU) in patients. This drug is able to offer this important new therapy to adults with PKU who are unable to control their [phenylalanine] levels with existing options

Competitive Analysis: Global Phenylketonuria (PKU) Treatment Market 

Global phenylketonuria (PKU) treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global phenylketonuria (PKU) treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players: Global Phenylketonuria (PKU) Treatment Market 

Few of the major competitors currently working in the global phenylketonuria (PKU) treatment market are  DAIICHI SANKYO COMPANY, LIMITED,  Ajinomoto Cambrooke, Inc., American Gene Technologies, Inc., Ultragenyx Pharmaceutical, Danone Nutricia , Reckitt Benckiser Group plc, Abbott, Promin Metabolics, Ajinomoto Cambrooke, Inc, Promin, Som innovation biotech, SL, Synthetic Biologics, Inc., Nestle,  Codexis, BioMarin, Erytech Pharma are the key market players.

Research Methodology: Global Phenylketonuria (PKU) Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts. Primary Respondents Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others. Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others. Reasons to Purchase this Report

  • Current and future of global phenylketonuria treatment market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions